Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) - A Multicentric Phase II Study in Patients With TKI-resistant EGFR-mutated Lung Cancer Exhibiting Early Metabolic Response to Osimertinib
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms THEROS
- 16 Apr 2019 Planned End Date changed from 1 Mar 2021 to 1 Dec 2022.
- 16 Apr 2019 Planned primary completion date changed from 1 Mar 2021 to 1 Dec 2021.
- 21 Nov 2018 New trial record